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Reduction of functioning parathyrold cell mass by ethanol injection In
chronic dialysis patients. Recent data suggest that the larger parathyroid
glands are more resistant to eateitriol therapy than the smaller glands due
to more severe reduction of calcitriol receptor number. To control severe
secondary hyperparathyroidism resistant to calcitriol pulse therapy in
chronic dialysis patients, we introduced repeatable and quantitative
ethanol injection(s) into the largest parathyroid gland under ultrasono-
graphic guidance with a specifically modified needle. Efficacy of each
injection and the recurrence of hyperparathyroidism were confirmed by
color Doppler ultrasonography and could undergo additional ethanol
injection(s) into the optimal site. When the ethanol injection(s) into the
largest gland was not sufficient to control PTH hypersecretion, we injected
ethanol into the next largest gland. We performed 32 injections into 16
parathyroid glands in nine dialysis patients. PTH decreased to less than
200 pg/mI after the final injection in seven patients and they remained
controlled either by the following conventional oral active vitamin D or
calcitriol pulse therapy. The other two patients, whose PTH decreased but
not to less than 200 pg/mi, also became controllable with the following
calcitriol pulse therapy. Recurrent nerve palsy was encountered in 2 out of
32 injections, but only transiently. Our data suggest that the measurement
of the size of parathyroid glands is an important factor in the management
strategy of secondary hyperparathyroidism in chronic dialysis patients, and
that ethanol injection(s) into the largest parathyroid gland(s) could be an
effective and safe strategy to restore the responsiveness to calcitriol
therapy, by reducing the functioning parathyroid cell mass most resistant
to calcitriol.
Secondary hyperparathyroidism with marked parathyroid hy-
perplasia is one of the most important complications of chronic
dialysis patients [1—3]. In addition to the basic therapies for
secondary hyperparathyroidism such as phosphate binders, phys-
iological doses of oral active vitamin D sterols, proper concentra-
tion of dialysate calcium, and calcitriol pulse therapy by giving ito
2 jig intravenous calcitriol [4—6] or 4 jig oral calcitriol [7, 8] per
dialysis has been widely used recently and has proved effective in
controlling severe forms of hyperparathyroidism in many chronic
dialysis patients. Since resistance of parathyroid cells to the
physiological concentration of calcitriol [9, 10], probably due to
the decrease of calcitriol receptor number [11—13], has been
recently considered one of the main causes of secondary hyper-
parathyroidism in chronic renal failure, calcitriol pulse therapy is
theoretically the most potent therapy practically available to
suppress parathyroid hormone (PTH) hypersecretion. However,
hyperparathyroidism may not be responsive even to calcitriol
pulse therapy in some dialysis patients and they tend to have
larger parathyroid glands than those of the responsive patients
[14, 15]. Consistent with such clinical observations, large parathy-
roid glands have been shown to be nodular hyperplasia with
higher proliferative potential [16, 17] and with lower number of
ealcitriol receptor [18]. Thus, it is rational to consider that the
largest parathyroid gland represents functioning parathyroid cells
most resistant to calcitriol.
Ethanol injection into the enlarged parathyroid glands was
developed as an alternative to parathyroidectomy and has been
shown to be effective and safe in the special cases [19—22].
However, ethanol injection is a difficult procedure for quantitative
parathyroid mass reduction, it may require skilled physicians and
may cause recurrent nerve palsy. Moreover, hyperparathyroidism
or hyperplasia may recur in the same glands which had undergone
ethanol injection, and under such circumstances sonographic or
surgical identification of functioning parathyroid mass may be-
come often difficult due to fibrosis.
Based on these backgrounds, we tried to restore the respon-
siveness of parathyroid to calcitriol therapy by injecting ethanol
into the largest gland(s) in the chronic dialysis patients who were
refractory to calcitriol pulse therapy. Furthermore, in order to
improve the efficacy and clinical usefulness of ethanol injection
into the parathyroid glands of chronic dialysis patients, we devel-
oped a modified needle and also introduced color flow mapping
with color Doppler ultrasonography to confirm the efficacy of
ethanol injection and to detect the recurrence of parathyroid cell
proliferation in the fibrosed glands. We demonstrate in this paper
that reduction of functioning parathyroid mass by quantitative
and repeatable ethanol injection(s) into the largest gland(s) is
practically safe and effective adjunct to calcitriol therapy in
chronic dialysis patients.
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Methods
Nine chronic dialysis patients with the evidence of very severe
hyperparathyroidism were referred to Showa General Hospital
because they were resistant to calcitriol pulse therapy. They had
been on maintenance dialysis for 11.8 2.6 years (mean SD),
thus, their residual renal function was considered to have no effect
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Fig. 1. A modified needle for ethanol injection
used in the present study. The tip is blind and
three holes are just adjacent to the tip allowing
easier identification of the tip in the center of
the parathyroid gland under ultrasonographic
guidance and more reliable delivery of ethanol
to the center of the gland.
on the severity of secondary hyperparathyroidism. The causes of
end-stage renal failure were chronic glomerulonephritis in five
patients (non-diabetic), diabetic nephropathy in one patient, and
undetermined (non-diabetic) in three patients. No patient had
been treated by steroids either before or during the study.
These nine patients had been treated by oral calcitriol pulse
therapy (2 to 4 p.g twice or three times per week) to control
hyperparathyroidism, and when the therapy was considered a
failure with persistent or recurrent severe hyperparathyroidism
and surgical parathyroidectomy was indicated, we elected to try
ethanol injections into their enlarged glands. The hyperplastic
glands were examined by ultrasonography using a 7.5 or 10 MH
mechanical inline sector scanner (SSD 650, Aloka, Tokyo, Japan)
and their sizes were estimated by the measurement of three
dimensions of the glands as reported earlier [8, 14]. The detection
limit of our sonographic technique was as small as 0.4 X 0.2 X 0.2
cm (0.008 cm3); however, we could not detect normal parathyroid
glands probably because of their echogenic density. As a protocol,
we chose the largest gland for the first ethanol injection, and when
indicated the next largest gland(s) underwent ethanol injections.
In case we should evaluate the recurrence of parathyroid cell
proliferation or hyperplasia in already sclerosed, though incom-
pletely, glands by prior ethanol injection, we routinely employed
color Doppler ultrasonography (Aloka, Tokyo or Acuson, Moun-
tain View, California, USA) with 7 or 7.5 MHz scanner specifically
tuned for the detection of hypervascularity of the parathyroid
glands in order to assess blood flow to the once scierosed gland.
The ethanol injection was performed with a needle specially
made for the injection into parathyroid glands. The needle was of
22 gauge and its tip was blind with three small side holes within 3.5
mm from the tip for ethanol introduction (Fig. 1). The surface
around the side holes was processed so that the tip and three side
holes of the needle can be easily recognized under ultrasonogra-
phy (Fig. 2). The needle was introduced into the largest parathy-
roid gland under ultrasonographic guidance to the position where
the side holes were in the center of the gland with a patient being
in a recumbent position with his neck extended over a pillow.
Ethanol was injected slowly over one to two minutes and its
diffusion into the gland could be monitored by observing changes
(becomes brighter) in echogenicity of the glands.
To avoid unnecessary excess ethanol infiltration to adjacent
thyroid, recurrent nerve, and other tissues, we chose the amount
of ethanol to be injected each time as 70% of the calculated gland
volume. When the volume of the gland was larger than 1 cm3, we
injected 50% of the calculated volume and repeated injections
several times at an interval of one week. In such cases, we
optimized the position of the needle, by using color Doppler
ultrasonography, so that we could inject ethanol into the remain-
ing parathyroid tissue with the highest blood supply, that is the
most functioning cells.
We estimated the effect of ethanol injection by serum PTH
concentration at one week after each injection. According to our
pilot study, successful destruction of the parathyroid tissue usually
led to suppression of PTH after one week of the injection. For
those patients with only one enlarged parathyroid gland, we
repeated the injection several times at an interval of one week
until serum PTH decreased to less than 200 pg/mI. Then they were
followed with conventional oral active vitamin D therapy (0.25 to
0.5 g of calcitriol or acalcidol daily) to maintain physiological
concentration of active vitamin D in circulation. In case P11-I did
not decrease to less than 200 pg/mI in these patients despite the
repeated ethanol injections with color Doppler ultrasonography,
they were further treated by oral calcitriol pulse therapy (4 g
twice or three times per week).
For those patients with multiple enlarged glands, we first
injected ethanol into the largest gland of each patient. When
serum PTH decreased to less than 200 pg/mI by single or multiple
ethanol injection(s), they were controlled by oral calcitriol pulse
therapy thereafter. When serum PTH failed to decrease to less
than 200 pg/mI despite the effective parathyroid tissue destruction
verified by usual and color Doppler ultrasonography, they were
then treated by oral calcitriol pulse therapy and we also injected
ethanol into the next largest gland. We repeated such process
until serum PTH decreased to less than 200 pg/ml and they were
further controlled either by oral calcitriol pulse therapy or con-
ventional oral active vitamin D therapy unless serum PTH became
too low (usually less than 100 pg/mI) or alkaline phosphatase
activity became lower than the normal limit (74 to 223 lU/liter) to
avoid too much suppression of bone turnover [23].
Even if serum PTH once became controlled to less than 200
pg/mI, the patients were still treated either by oral calcitriol pulse
therapy or conventional active vitamin D therapy, and serum PTH
Fig. 2. lp of the injection needle within parathymid gland detected ?y ulinzsonography.
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Fig. 2. Tip of the injection needle within parathyroid gland detected by ultrasonography.
was checked every two weeks. When any evidence of recurrence
of hyperparathyroidism became apparent, we again monitored
their parathyroid gland size by ultrasonography and cheek the
evidence of active cell proliferation by color Doppler ultrasonog-
raphy and performed additional ethanol injection(s) if necessary.
During the study, the doses of oral phosphate binders remained
unchanged as a rule. Dialyses were performed three times per
week with standard bicarbonate dialysate. Duration of each
dialysis was at least four hours and dialysis protocols were not
changed during the study.
Serum immunoreactive PTH levels were measured by the
two-antibody method using Allegro Intact PTH Kit (Nichols
Institute, San Juan Capistrano, California, USA) [24]. Other
serum parameters were measured by an automated analyzer.
Results
Our experience of ethanol injection into the parathyroid glands
in nine chronic dialysis patients is summarized in Table 1. In total,
we performed 32 injections into 16 parathyroid glands in nine
dialysis patients within 12 weeks. Ethanol injection(s) into the
largest gland was enough in three eases, while additional injec-
tion(s) into the second or the third largest glands was necessary in
six patients. Nevertheless, it was of note that we did not always
need to inject ethanol into all of the detectable parathyroid glands
in order to control hyperparathyroidism (cases #2 and #3).
Severe secondary hypeiparathyroidism, resistant even to calcitriol
pulse therapy before ethanol injection, became suppressed (PTH
<200 pg/ml) in seven patients at one week after the final ethanol
injection, and they remained controlled thereafter with oral
caleitriol pulse therapy in four patients and with conventional oral
active vitamin D therapy in three patients. In the other two
patients, PTH did not decrease to less than 200 pg/mI after one
week of the final ethanol injection, despite complete destruction
of the injected gland verified by usual and color Doppler ultra-
sonography. However, PTH further decreased by calcitriol pulse
therapy, and then they became well controlled. Thus, it is also of
note that secondary hyperparathyroidism became responsive to
calcitriol therapy, even if PTH did not decrease to less than 200
pg/mi by ethanol injections alone. In case #1, severe hungry bone
syndrome [25] developed after a single ethanol injection, however,
the patient was well controlled with high dose of daily oral
calcitriol up to 4 gg [26].
Concerning the long-term prognosis, we followed these patients
for 14.9 8.0 months (6 to 36 months) after their final ethanol
injection. Their serum PTH levels were well controlled under 200
pg/mi except the case #9, in whom PTH was 370 pg/mi at 36
months after the final ethanol injection. Thus, the long-term
prognosis of this therapy was also quite good as long as they were
intensively managed by specialists.
Figure 3A shows a representative time course of a patient with
one large parathyroid gland (Fig. 3B) larger than 1 cm3 (1.3 X 1.3
>< 1.3 cm; case #8). According to the protocol, we injected the
reduced amount of ethanol into this gland divided into four times
with the help of color Doppler uitrasonography to detect the
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Table 1. Ethanol injection into parathyroid glands of nine chronic dialysis patients
PTH pg/mi Alpase lU/liter cCa'/Pi mg/dl
1 week 1 week 1 week
1 week after 1 week after 1 week after Number Number Number Course from
before the before the before the Calcitriol of of of total the first to the
the first final the first final the first final pulse injected detected injections final PELT
Case Age Sex PElT PELT PElT PElT PELT PElT therapy glands glands times weeks
1 58 M 1010 86 391 824 11.2/5.6 7.8/3.2 (_)b 1 1 1 0
2 43 F 698 122 465 115 11.0/5.6 7.8/4.7 (+) 2 3 5 8
3 55 M 190 90 149 127 10.9/6.9 10.2/5.2 (—) 1 2 2 6
4 62 F 266 107 244 159 13.2/4.4 11.8/3.5 (+) 2 2 4 8
5 57 M 598 118 309 112 11.2/6.9 10.5/6.0 (+) 3 3 5 12
6 43 M 1120 340C 294 188 10.9/6.0 9.9/5.7 (-I-) 2 2 2 6
7 49 F 695 200 243 182 11.1/6.8 10.9/4.7 (+) 2 2 5 12
8 65 M 790 97 338 380 9.8/7.2 9.8/4.7 (—) 1 1 4 5
9 47 M 1180 410 1084 128 9.6/6.6 9.0/6.6 (+) 2 2 4 8
Abbreviations are: PElT, percutaneous ethanol injection; Alpase, serum alkaline phosphatase activity; Pi, inorganic phosphate concentration.
a Serum calcium was corrected for albumin concentration.
"Due to hungry bone syndrome, large dose of calcitriol was needed daily.
PTH did not decrease to less than 200 pg/mI after 1 week of the final ethanol injection, PTH further decreased by calcitriol pulse therapy.
remaining tissue, Secondary hyperparathyroidism in this patient
became suppressed to less than 200 pg/mI and he remained control-
lable with conventional oral active vitamin D therapy alone,
Figure 4A shows a representative time course of a patient with
multiple enlarged glands. In this patient (case #6), two enlarged
parathyroid glands were detectable by ultrasonography (Fig. 4B).
We first injected ethanol into the largest gland (0.9 x 1.2 X 1.2
cm) and serum PTH was once suppressed significantly, but not to
less than 200 pg/mI. Nevertheless, his serum PTH began to
increase again at six weeks after the first injection despite
______________________________
calcitriol pulse therapy. When secondary hyperparathyroidism
relapsed as in this case after the ethanol injection(s) into the
largest gland(s), we assessed the recurrence of parathyroid cell
proliferation within the sclerotic tissue after the therapy with color
Doppler ultrasonography by detecting difference in blood flow
between fibrotic parathyroid tissue and functioning parathyroid
cells growing and becoming hyperplastic around the fibrotic gland.
In case #6, no recurrence was detectable in the largest gland
injected, thus we next performed ethanol injection into the second
largest gland (0.8 >< 0.7 x 1.0 cm). After the injection into the
second largest gland, secondary hyperparathyroidism in this pa-
tient became controllable with calcitriol pulse therapy.
In some other cases with relapsed hyperparathyroidism, we
could detect the sign of growing parathyroid cells within the
injected gland as shown in Figure 5A. With such information, we
could introduce ethanol again into the functioning parathyroid
cell mass. After one week of the additional injection, the blood
flow around the tissue could not be detectable any more (Fig. 5B),
leading to the suppression of hyperparathyroidism.
As for the complication, recurrent nerve palsy was encountered
in two of 32 ethanol injection trials in nine patients; however, both
of them were transient and completely reversible.
Discussion
Secondary hyperparathyroidism with marked parathyroid hy-
perplasia is the central feature of uremic bone disease [1—3]. One
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Fig. 3. A. A representative dialysis patient with a single enlarged parathyroid
gland larger than 1 cmi. Repeated percutaneous ethanol injections (PElT)
into the gland led to the effective control of parathyroid hormone
hypersecretion. Symbols are: (U) serum PTH concentration; and (•)
serum alkaline phosphatase activity. B. The enlarged parathyroid (P) of
this patient measured 1.3 X 1.3 X 1.3 cm.
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Fig. 4. A. A representative chronic dialysis patient who underwent two
percutaneous ethanol injections (PElT) on two different occasions into the
two enlarged parathyroid glands. Note that following the first ethanol
injection into the largest parathyroid gland (B 1), PTH fell to the targeted
range, but then rose again, which could be controlled initially by calcitriol
pulse therapy. When PT!-! rose again despite caleitriol pulse therapy,
second ethanol injection into the next largest gland (B 2) was performed
and it led to the reduction in FF11 to the targeted range. Symbols are: (•)
serum PTH concentration; and (•) serum alkaline phosphatase activity.
B. (left) The largest parathyroid gland (0.9 x 1.2 x 1.2 cm). (right) The
second largest parathyroid gland (0.8 )< 0.7 X 1.0 cm).
of the main mechanisms of secondary hyperparathyroidism has
been recently attributed to the resistance of parathyroid cells to
physiological concentration of calcitriol [8, 9], which may be the
result of decreased ealcitriol receptor number [11—13]. Despite
the introduction of calcitriol pulse therapy to attain supraphysi-
ological concentration of ealcitriol in circulation [4—8], it is
sometimes still difficult to suppress PTH hypersecretion in chronic
dialysis patients.
Severity of secondary hyperparathyroidism or its responsiveness
to calcitriol therapy does not always depend upon the magnitude
of PTH hypersecretion, but may depend upon other factors such
as the magnitude of parathyroid hyperplasia and the number of
enlarged glands [14, 27, 28]. MeCarron and associates first showed
that parathyroid size correlates not with basal PTH concentration,
but with stimulated peak PTI-I secretion [29]. Since the peak PTH
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secretion per cell was not different from normal parathyroid cells
500 [30], such higher stimulated peak PTH was attributed to theincrease of cell numbers. Nevertheless, other reports suggested
that there was a difference not only in cell quantity but also in cell
quality [31], such as the shift of set point [32], which can be
modified by calcitriol [33]. Thus, several data have accumulated
suggesting that the larger parathyroid glands are composed of
cells more proliferative and more resistant to calcitriol than those
of the smaller parathyroid glands [14—18]. In special cases,
monoclonal proliferation of the parathyroid cells [34] or even a
genetic mutation that lead to autonomous proliferation of para-
thyroid cells [35] has been reported in chronic dialysis patients.
Although calcitriol has been shown to suppress parathyroid cell
proliferation [8, 36, 37] as well as PTH secretion and synthesis [9,
38], it may be impossible to control parathyroid hyperplasia in
such resistant cases. Taking such evidence into account, it is a
reasonable strategy to delete most functioning parathyroid mass
by injecting ethanol into the largest gland(s) to restore the
responsiveness of secondary hyperparathyroidism to calcitriol in
chronic dialysis patients.
Our present data suggest that the larger glands are primarily
responsible for excess secretion of PT!-! and that these large
glands may become resistant to conventional oral active vitamin D
or caleitriol pulse therapy. The fact that plasma PTH concentra-
tion could be controlled by caleitriol therapy following ethanol
injection(s) suggests that the remaining parathyroid glands are
more responsive to calcitriol. These data clearly indicate that the
sensitivity of parathyroid glands to caleitriol may differ even in the
same patient and that the size of the gland is an important
determinant of the sensitivity to calcitriol, as we have reported in
the recent study [14]. The data are consistent with the observa-
tions in chronic dialysis patients which suggest that the large
parathyroid glands tend to show nodular hyperplasia rather than
diffuse hyperplasia [15] and that these nodular hyperplastic glands
have higher proliferative potential [16] and higher recurrence rate
when they were autotransplanted [17]. Furthermore, we have
recently shown that the nodular hyperplastie glands show severer
reduction in calcitriol receptor density compared with the diffuse
hyperplastic glands [18]. It is likely that when the density of
caleitriol receptor becomes less, higher ealcitriol concentration
will be necessary to form a sufficient amount of ealcitriol-receptor
complex to exert its action in target cells [39]. Thus, one could
reason why the larger parathyroid glands may be more resistant to
calcitriol pulse therapy and why the measurement of the parathy-
roid gland size would serve as an important index in the manage-
ment strategy of secondary hyperparathyroidism in chronic dial-
ysis patients.
Percutaneous ethanol injection into parathyroid glands under
ultrasonography was first introduced as a practical procedure by
Italian group [19] and there have been several case reports of the
successful ethanol injections [21, 22]. In their recent report [20],
Giangrande and associates summarized their experience of etha-
nol injection in 50 dialysis patient for 10 years with 60% overall
success rate. With technical progress, they gained better results by
injections into all the detectable glands or by repeated injections
in some eases. Thus, the percutaneous ethanol injection has been
recognized as an effective and safe way to suppress secondary
hyperparathyroidism or as an alternative to surgical parathyroid-
ectomy. Nevertheless, there has been no consensus yet on the
indication or protocol, that is, which patients, which glands, how
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Fig. 5. Color Doppler ultrasonographic visualization of relapsed parathyroid cell proliferation around the fibrotic parathyroid gland in a representative case.
Note the significant blood flow (red color in A) in the functioning parathyroid cell mass. Ethanol injection into the functioning cell mass effectively
abolished the blood flow and presumably induced its necrosis at one week after the injection (B).
many glands, how much or how many times ethanol should be
injected. Our study, together with other clinical or biological
observations, can not only improve the efficacy of this procedure
but also propose more rational indication and protocol of this
procedure. Additional trials should be necessary to further opti-
mize the protocol so as to avoid unnecessary injections.
One of the significant problems of ethanol injection into the
parathyroid glands in chronic dialysis patients is the possibility
that subsequent surgical removal of the parathyroid gland which
had undergone ethanol injection, should it become necessary, may
become difficult due in part to fibrosis of parathyroid glands and
other surrounding tissues. Moreover, identification of functioning
parathyroid cells originating from the glands, a portion of which
had been fibrotic by ethanol injection, may be extremely difficult.
It is possible that these cells proliferating around the gland share
properties similar to the cells of the originally enlarged gland, thus
may also be resistant to calcitriol. Nevertheless, we have found it
useful to employ color Doppler ultrasonography to detect the
recurrent parathyroid cell mass surrounding the gland, which
could undergo additional ethanol injection. Furthermore, color
Doppler ultrasonography was also useful to evaluate and to
localize the functioning tissue remained after the prior injections
with insufficient results. Thus, our procedure could be more
quantitative and reasonably repeatable.
Another major complication of ethanol injection into parathy-
roid glands is the recurrent nerve palsy. It has been reported that
the recurrent nerve palsy may be seen in 5 to 10% of the patients
following ethanol injection, but it was transient in most cases [201.
It is of note that our needle was modified so that the side holes of
the needle could be advanced to the center of the enlarged gland
with more accuracy for ethanol to diffuse within the gland. With a
conventional needle which has a sharp tip and a diagonal opening,
the possible diffusion of ethanol to tissues surrounding the
enlarged parathyroid gland may not be avoidable, thus increasing
the possibility of recurrent nerve palsy. In addition, to avoid
injecting the very large amount of ethanol which may be more
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likely to diffuse out of parathyroid, we further reduced the volume
of injected ethanol to 50% of calculated gland volume if the gland
was larger than 1 cm3. Such small volume could only destroy a part
of a large gland, however, we could repeat the injections by
identifying the functioning part of the large gland by color
Doppler ultrasonography. Thus, we believe that our procedure is
more effective, rational and safer than before with the help of a
special needle, repeated injections with smaller volume of etha-
nol, and color Doppler ultrasonography.
In addition to the case #1 in this study, we had experienced
some cases of severe hungry bone syndrome after ethanol injec-
tion before this study began. All of these patients had very high
serum PTH and had a single, very large (>1 cm3) parathyroid
gland. Thus, such patients should be carefully followed after the
ethanol injection and the volume of ethanol per injection should
be reduced as our protocol.
With the technical and theoretical progress shown in this paper,
we believe that ethanol injection can be the first alternative for
surgical parathyroidectomy especially for the patients with smaller
and/or fewer enlarged glands or for the high risk patients. In the
patients with multiple and very large glands, we still consider
surgical parathyroidectomy by well-trained parathyroid surgeon as
the first choice because of the risk of recurrent nerve palsy and
hungry bone syndrome, as well as higher medical cost for repeated
injections. Nevertheless, further technological development may
make it possible to treat them more safely and efficiently by
ethanol injection.
In conclusion, our observations in the limited number of
chronic dialysis patients suggest that the measurement of para-
thyroid gland mass is an important component in the assessment
of secondary hyperparathyroidism, because larger parathyroid
glands are more resistant to calcitriol pulse therapy. Thus, we
propose ethanol injection into the largest gland(s) as a useful
strategy to control hyperparathyroidism by reducing parathyroid
cell mass much more resistant to calcitriol in chronic dialysis
patients.
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